| |
|
|
|
|
|
 |
| |
|
³ëÆæ24øºÎÁ¦(µðŬ·ÎÆä³«µð¿¡Æ¿¾Ï¸ð´½) Nofen 24 Plaster
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644900530
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¿¯Àº ³ë¶õ»öÀÇ Á¡Âø¼º ¹°ÁúÀ» »ì±¸»ö¸°Æ®Æ÷¿¡ µµÆ÷ÇÏ¿© °íü¸é¿¡ ¹Ú¸®Áö¸¦ µ¤Àº øºÎÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10¸Å
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 120¹Ð¸®±×·¥ |
30 ¸Å |
Æ÷ |
8806449005307 |
8806449005338 |
|
| 120¹Ð¸®±×·¥ |
10 ¸Å |
Æ÷ |
8806449005307 |
8806449005321 |
|
| 120¹Ð¸®±×·¥ |
7 ¸Å |
Æ÷ |
8806449005307 |
8806449005314 |
|
|
| ÁÖ¼ººÐÄÚµå |
143302CPL
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ ¹× Áõ»óÀÇ ÁøÅë, ¼Ò¿°(Ç׿°)
1) º¯Çü¼º°üÀý¿°
2) °ß°üÀýÁÖÀ§¿°(¾î±ú°üÀýÁÖÀ§¿°)
3) °Ç(ÈûÁÙ)¤ý°ÇÃÊ¿°(ÈûÁÙÀ±È°¸·¿°)
4) °ÇÁÖÀ§¿°(ÈûÁÙÁÖÀ§¿°)
5) »ó¿Ï°ñ»ó°ú¿°(À§ÆÈ»À»ó°ú¿°) (Å״Ͻº ¿¤º¸¿ì µî)
6) ¿Ü»ó ÈÄÀÇ Á¾Ã¢¤ýµ¿Åë(»óóÈÄÀÇ ºÎ±â¤ýÅëÁõ) (Ÿ¹Ú, Á»ó(Ÿ¹Ú»ó/¸Û), ¿°ÁÂ(»ã) µî)
7) ±ÙÀ°Åë
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ȯºÎ(ÁúȯºÎÀ§)¿¡ 1ÀÏ 1ȸ ºÎÂøÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ Àü·ÂÀÌ Àִ ȯÀÚ
2) ¾Æ½ºÇǸ° õ½Ä(ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦ µî¿¡ õ½Ä¹ßÀÛÀÇ À¯¹ß) ¶Ç´Â ±× Àü·ÂÀÌ Àִ ȯÀÚ
3) ÀӽŠ3±â |
| ½ÅÁßÅõ¿© |
1) ±â°üÁö õ½Ä ȯÀÚ
2) ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î À̼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±âº´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.(ÇÔÀ¯Á¦Ç°¿¡ ÇÑÇÔ) |
| ÀÌ»ó¹ÝÀÀ |
1) ÇǺΠ: ÀÌ ¾àÀº Å»¶ô¼º ÇǺο°, ½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº ¹× µ¶¼º Ç¥ÇDZ«»ç °°Àº Áß´ëÇÑ ÇǺΠÀÌ»ó¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀº °æ°í Áõ»ó ¾øÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ´ëºÎºÐÀÇ °æ¿ì ÀÌ·¯ÇÑ ÀÌ»ó¹ÝÀÀÀº Åõ¿© Ãʱâ 1°³¿ù À̳»¿¡ ¹ß»ýÇÑ´Ù. ȯÀÚ´Â Áß´ëÇÑ ÇǺΠ¹ßÇö Áõ»ó ¹× ÁõÈÄ¿¡ ´ëÇØ ¾Ë°í ÀÖ¾î¾ß ÇÏ¸ç ¶§¶§·Î ¹ßÀû, ¹ßÁø, °¡·Á¿òÁõ, ÇǺΰÇÁ¶ ¹× Àڱذ¨ ¶Ç´Â µå¹°°Ô Á¾Ã¢ÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ½ÉÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) °ú¹ÎÁõ : µå¹°°Ô ¾Æ³ªÇʶô½Ã¾çÁõ»ó(µÎµå·¯±â, È£Èí°ï¶õ µî)ÀÌ ³ªÅ¸³ª´Â °æ¿ì°¡ ÀÖÀ¸¹Ç·Î ÀÌ·± Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
(øºÎÁ¦ )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Diclofenac¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of ketoprofen. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.
|
| Pharmacology |
Diclofenac¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diclofenac is an acetic acid nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Diclofenac is used to treat pain, dysmenorrhea, ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and actinic keratosis
|
| Metabolism |
Diclofenac¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C9 (CYP2C9)Cytochrome P450 2C19 (CYP2C19)Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2C8 (CYP2C8)Cytochrome P450 2D6 (CYP2D6)Glucuronosyltransferase
|
| Protein Binding |
Diclofenac¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ More than 99%
|
| Half-life |
Diclofenac¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2 hours
|
| Absorption |
Diclofenac¿¡ ´ëÇÑ Absorption Á¤º¸ Completely absorbed from the gastrointestinal tract.
|
| Pharmacokinetics |
Diclofenac diethylammoniumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : 99%
- ´ë»ç : °£¿¡¼ ºñȰ¼ºÇü ´ë»çü·Î ´ë»çµÊ
- ¹Ý°¨±â : 2½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 1-2 ½Ã°£ À̳»
- ¼Ò½Ç : ÁÖ·Î ½Å¹è¼³
|
| Biotransformation |
Diclofenac¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Diclofenac¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis. LD50=390mg/kg (orally in mice)
|
| Drug Interactions |
Diclofenac¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Increased risk of gastric toxicityAnisindione The NSAID increases the anticoagulant effectCyclosporine Monitor for nephrotoxicityDicumarol The NSAID increases the anticoagulant effectWarfarin The NSAID increases the anticoagulant effectRifampin Decreased levels/effect of the NSAID
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Diclofenac¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2C9
NSAIDs:
**diclofenac**
ibuprofen
piroxicam
Oral Hypoglycemic Agents:
tolbutamide
glipizide
Angiotensin II Blockers:
NOT candesartan
irbesartan
losartan
NOT valsartan
celecoxib
fluvastatin naproxen
phenytoin
sulfamethoxazole
tamoxifen
tolbutamide
torsemide
warfarin
INHIBITORS
CYP 2C9
amiodarone
fluconazole
isoniazid
INDUCERS
CYP 2C9
rifampin
secobarbital
|
| Food Interaction |
Diclofenac¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation.Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Diclofenac¿¡ ´ëÇÑ Description Á¤º¸ A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]
|
| Drug Category |
Diclofenac¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase InhibitorsNonsteroidal Antiinflammatory Agents (NSAIDs)
|
| Smiles String Canonical |
Diclofenac¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
|
| Smiles String Isomeric |
Diclofenac¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
|
| InChI Identifier |
Diclofenac¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)/f/h18H
|
| Chemical IUPAC Name |
Diclofenac¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid
|
| Drug-Induced Toxicity Related Proteins |
DICLOFENAC ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:CYP3A4 Drug:Diclofenac Toxicity:idiosyncratic hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:CYP2C9 Drug:Diclofenac Toxicity:idiosyncratic hepatotoxicity. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. DICLOFENAC[GGT Increase][Composite Activity](Score) A(Marginal) 1(Active) 3[Alkaline Phosphatase Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 9.2[SGOT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 11.4[SGPT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 11.1[LDH Increase](Activity Score) I(Number of Rpts) ¡Ã4(Index value) 2[GGT Increase](Activity Score) M(Number of Rpts) ¡Ã4(Index value) 3.8
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|